BR0014761A - Derivados de benzodiazepina - Google Patents
Derivados de benzodiazepinaInfo
- Publication number
- BR0014761A BR0014761A BR0014761-3A BR0014761A BR0014761A BR 0014761 A BR0014761 A BR 0014761A BR 0014761 A BR0014761 A BR 0014761A BR 0014761 A BR0014761 A BR 0014761A
- Authority
- BR
- Brazil
- Prior art keywords
- benzodiazepine derivatives
- present
- compounds
- psychosis
- thiophenyl
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Patente de Invenção: "DERIVADOS DE BENZODIAZEPINA". A presente invenção refere-se a compostos de fórmula geral (I) em que R^ 3^ é fenila; piridina; tiofenila ou tiazolila, os quais são opcionalmente substituídos. Os compostos de acordo com a presente invenção podem ser usados para tratamento ou prevenção de distúrbios neurológicos agudos e/ou crónicos tais como psicose, esquizofrenia, mal de Alzheimer, distúrbios cognitivos e déficits da memória.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99120519 | 1999-10-15 | ||
| PCT/EP2000/009554 WO2001029012A2 (en) | 1999-10-15 | 2000-09-29 | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014761A true BR0014761A (pt) | 2002-07-02 |
Family
ID=8239206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014761-3A BR0014761A (pt) | 1999-10-15 | 2000-09-29 | Derivados de benzodiazepina |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US6509328B1 (pt) |
| EP (1) | EP1224175B1 (pt) |
| JP (1) | JP3886805B2 (pt) |
| KR (1) | KR100481386B1 (pt) |
| CN (1) | CN1199954C (pt) |
| AR (1) | AR026028A1 (pt) |
| AT (1) | ATE261945T1 (pt) |
| AU (1) | AU779874B2 (pt) |
| BR (1) | BR0014761A (pt) |
| CA (1) | CA2386980C (pt) |
| CO (1) | CO5251454A1 (pt) |
| CZ (1) | CZ20021663A3 (pt) |
| DE (1) | DE60009116T2 (pt) |
| DK (1) | DK1224175T3 (pt) |
| ES (1) | ES2215738T3 (pt) |
| GC (1) | GC0000207A (pt) |
| HR (1) | HRP20020260B1 (pt) |
| HU (1) | HUP0203294A3 (pt) |
| IL (2) | IL149104A0 (pt) |
| JO (1) | JO2299B1 (pt) |
| MA (1) | MA26832A1 (pt) |
| MX (1) | MXPA02003740A (pt) |
| MY (1) | MY125506A (pt) |
| NO (1) | NO20021691D0 (pt) |
| NZ (1) | NZ518037A (pt) |
| PE (1) | PE20010759A1 (pt) |
| PL (1) | PL357433A1 (pt) |
| PT (1) | PT1224175E (pt) |
| RU (1) | RU2257382C2 (pt) |
| SI (1) | SI1224175T1 (pt) |
| TR (1) | TR200201026T2 (pt) |
| TW (1) | TWI254044B (pt) |
| WO (1) | WO2001029012A2 (pt) |
| YU (1) | YU27902A (pt) |
| ZA (1) | ZA200202654B (pt) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779874B2 (en) | 1999-10-15 | 2005-02-17 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives |
| HRP20030791B1 (en) * | 2001-04-12 | 2006-06-30 | F. Hoffmann - La Roche Ag | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I |
| EP1379511B1 (en) * | 2001-04-12 | 2005-07-20 | F. Hoffmann-La Roche Ag | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| US7531529B2 (en) * | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| PL1651234T3 (pl) * | 2003-07-25 | 2008-02-29 | Hoffmann La Roche | Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych |
| HRP20080363T3 (hr) | 2004-06-01 | 2008-09-30 | F. Hoffmann - La Roche Ag | Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora |
| EP1812392B1 (en) | 2004-11-05 | 2008-07-09 | F.Hoffmann-La Roche Ag | Process for preparation of isonicotinic acid derivatives |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CA2633263A1 (en) * | 2005-12-16 | 2007-07-12 | Arkema Inc. | Low surface energy block co-polymer preparation methods and applications |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080188714A1 (en) * | 2007-02-07 | 2008-08-07 | Boston Scientific Scimed, Inc. | Electromechanical in-situ cleaning of optical elements |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| MX2009010729A (es) | 2007-04-19 | 2009-10-26 | Hoffmann La Roche | Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida. |
| BRPI0816970A2 (pt) * | 2007-09-14 | 2015-03-24 | Ortho Mcneil Janssen Pharm | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
| CA2704436C (en) | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US8193363B2 (en) | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012015024A1 (ja) | 2010-07-29 | 2012-02-02 | 大正製薬株式会社 | エチニル－ピラゾール誘導体 |
| US20130137865A1 (en) | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN102276592B (zh) * | 2011-06-17 | 2013-10-16 | 大连理工大学 | 一种奥氮平有关物质及其制备方法、分析方法 |
| US9193710B2 (en) | 2011-08-29 | 2015-11-24 | Sanford-Burnham Medical Research Institute | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| US9278960B2 (en) * | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| HK1206615A1 (en) | 2012-10-23 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Mglu2/3 antagonists for the treatment of autistic disorders |
| CN102936223A (zh) * | 2012-11-02 | 2013-02-20 | 江苏中丹药物研究有限公司 | 5-碘-2-甲基苯并咪唑的合成方法及纯化方法 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| MX2016013711A (es) | 2014-04-23 | 2017-01-13 | Hoffmann La Roche | Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales. |
| US9969726B2 (en) | 2014-06-10 | 2018-05-15 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof |
| CN108586447B (zh) * | 2018-01-19 | 2021-01-29 | 中国人民解放军第四军医大学 | 一种苯二氮杂卓化合物及其制备方法和应用 |
| CN108624674B (zh) * | 2018-03-30 | 2020-11-24 | 青岛泱深生物医药有限公司 | Krt73作为分子靶标在帕金森诊治中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2053680A1 (de) * | 1970-11-02 | 1972-05-18 | CH. Boehringer Sohn, 6507 Ingelheim | Neue 2-Amino-dihydro-benzodiazepinone |
| SU749836A1 (ru) * | 1978-02-13 | 1980-07-23 | Днепропетровский Ордена Трудового Красного Знамени Государственный Университет Им. 300-Летия Воссоединения Украины С Россией | Способ получени 4-метил2,3-дигидро1н-1,5-бензодиазепинонов-2 |
| JPS6032775A (ja) | 1983-07-30 | 1985-02-19 | Daikin Ind Ltd | 含フッ素ベンゾジアゼピン類 |
| GB8601004D0 (en) | 1986-01-16 | 1986-02-19 | Fujisawa Pharmaceutical Co | 1,5-benzodiazepine derivatives |
| GB9018601D0 (en) | 1990-08-24 | 1990-10-10 | Fujisawa Pharmaceutical Co | Tricyclic compounds |
| CA2054455A1 (en) | 1990-11-23 | 1992-05-24 | John James Delany | Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides |
| ATE207064T1 (de) | 1992-07-29 | 2001-11-15 | Merck Sharp & Dohme | Benzodiazepinderivate |
| GB9314981D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Spa | Chemical compounds |
| AU3414295A (en) | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
| WO1997005109A1 (en) * | 1995-07-31 | 1997-02-13 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| PL193686B1 (pl) | 1995-09-07 | 2007-03-30 | Hoffmann La Roche | Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych |
| AU771358B2 (en) * | 1997-11-21 | 2004-03-18 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| TR200201023T2 (tr) | 1999-10-15 | 2002-09-23 | F. Hoffmann-La Roche Ag | Benzodiazepin türevleri. |
| AU779874B2 (en) | 1999-10-15 | 2005-02-17 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives |
| HRP20030791B1 (en) * | 2001-04-12 | 2006-06-30 | F. Hoffmann - La Roche Ag | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I |
| EP1379511B1 (en) * | 2001-04-12 | 2005-07-20 | F. Hoffmann-La Roche Ag | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
-
2000
- 2000-09-29 AU AU10204/01A patent/AU779874B2/en not_active Ceased
- 2000-09-29 AT AT00971302T patent/ATE261945T1/de not_active IP Right Cessation
- 2000-09-29 NZ NZ518037A patent/NZ518037A/en unknown
- 2000-09-29 YU YU27902A patent/YU27902A/sh unknown
- 2000-09-29 CN CNB008142211A patent/CN1199954C/zh not_active Expired - Fee Related
- 2000-09-29 BR BR0014761-3A patent/BR0014761A/pt not_active Application Discontinuation
- 2000-09-29 EP EP00971302A patent/EP1224175B1/en not_active Expired - Lifetime
- 2000-09-29 JP JP2001531812A patent/JP3886805B2/ja not_active Expired - Fee Related
- 2000-09-29 DK DK00971302T patent/DK1224175T3/da active
- 2000-09-29 KR KR10-2002-7004831A patent/KR100481386B1/ko not_active Expired - Fee Related
- 2000-09-29 PT PT00971302T patent/PT1224175E/pt unknown
- 2000-09-29 HR HR20020260 patent/HRP20020260B1/xx not_active IP Right Cessation
- 2000-09-29 ES ES00971302T patent/ES2215738T3/es not_active Expired - Lifetime
- 2000-09-29 WO PCT/EP2000/009554 patent/WO2001029012A2/en not_active Ceased
- 2000-09-29 MX MXPA02003740A patent/MXPA02003740A/es active IP Right Grant
- 2000-09-29 SI SI200030395T patent/SI1224175T1/xx unknown
- 2000-09-29 HU HU0203294A patent/HUP0203294A3/hu unknown
- 2000-09-29 PL PL00357433A patent/PL357433A1/xx not_active Application Discontinuation
- 2000-09-29 DE DE60009116T patent/DE60009116T2/de not_active Expired - Lifetime
- 2000-09-29 TR TR2002/01026T patent/TR200201026T2/xx unknown
- 2000-09-29 CA CA2386980A patent/CA2386980C/en not_active Expired - Fee Related
- 2000-09-29 CZ CZ20021663A patent/CZ20021663A3/cs unknown
- 2000-09-29 RU RU2002110107/04A patent/RU2257382C2/ru not_active IP Right Cessation
- 2000-09-29 IL IL14910400A patent/IL149104A0/xx active IP Right Grant
- 2000-10-07 TW TW089121013A patent/TWI254044B/zh not_active IP Right Cessation
- 2000-10-11 CO CO00077374A patent/CO5251454A1/es not_active Application Discontinuation
- 2000-10-11 JO JO2000170A patent/JO2299B1/en active
- 2000-10-11 GC GCP2000949 patent/GC0000207A/en active
- 2000-10-12 PE PE2000001096A patent/PE20010759A1/es not_active Application Discontinuation
- 2000-10-13 MY MYPI20004818A patent/MY125506A/en unknown
- 2000-10-13 US US09/687,241 patent/US6509328B1/en not_active Expired - Fee Related
- 2000-10-13 AR ARP000105385A patent/AR026028A1/es unknown
-
2002
- 2002-04-04 ZA ZA200202654A patent/ZA200202654B/en unknown
- 2002-04-10 NO NO20021691A patent/NO20021691D0/no not_active Application Discontinuation
- 2002-04-11 IL IL149104A patent/IL149104A/en not_active IP Right Cessation
- 2002-04-15 MA MA26602A patent/MA26832A1/fr unknown
- 2002-11-20 US US10/300,449 patent/US6960578B2/en not_active Expired - Fee Related
-
2005
- 2005-06-07 US US11/146,693 patent/US7018998B2/en not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/363,351 patent/US7151098B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU27902A (sh) | Derivati benzodiazepina | |
| BR0014859A (pt) | Derivados de benzodiazepina | |
| BR0214024A (pt) | Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina | |
| BR0214023A (pt) | Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| NO306464B1 (no) | Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter | |
| NZ595571A (en) | Pyrazole compounds and uses thereof | |
| BR9901095A (pt) | Pirazopirimidinas e pirazoltriazinas. | |
| BR0206495A (pt) | Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato | |
| BR0209678A (pt) | Composto, processo para preparar e uso do mesmo, composição farmacêutica, e, métodos para o tratamento da dor e de distúrbios gastrintestinais funcionais | |
| BR9908480A (pt) | Compostos heterocìclicos como inibidores de enzimas rotamase | |
| EP1689713A4 (en) | BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
| ATE401072T1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
| BR9706792A (pt) | Derivado de tiazol | |
| ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
| IL134812A0 (en) | Condensed thiophene derivatives and pharmaceutical compositions containing the same | |
| BR9912556A (pt) | Triazolpiridinas para o tratamento de distúrbios trombóticos | |
| DE69822937D1 (de) | Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen | |
| YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
| BR0317330A (pt) | Compostos orgânicos | |
| BRPI0410613A (pt) | preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |